Lasmiditan
Reyvow (lasmiditan) is a prescription oral tablet medication manufactured by Eli Lilly and Company, available in 50 mg and 100 mg strengths to treat acute migraines. The 200 mg strength has been discontinued. It is a controlled substance (CV schedule). This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Reyvow (lasmiditan) is a prescription oral tablet medication manufactured by Eli Lilly and Company, available in 50 mg and 100 mg strengths to treat acute migraines. The 200 mg strength has been discontinued. It is a controlled substance (CV schedule). This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Lasmiditan",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Lasmiditan — ANDA 211280 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211280"
}
]
|
| identifier | ANDA211280 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"health-care",
"medications",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Lasmiditan |
